This systematic review and meta-analysis of 24 randomized controlled trials assessed the effects of alpha-lipoic acid (ALA) supplementation on glycemic control and lipid profiles in patients with metabolic diseases. ALA dosages ranged from 200 to 1,800 mg/day over 2 to 51 weeks. The analysis found significant improvements in fasting glucose
